Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Planchard

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Revue De Pneumologie Clinique|October 12, 2010
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]J Margery, F Rivière, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerE Pailler, N Auger, C R Lindsay, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?M Macerelli, C Caramella, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumorsT Walter, D Planchard, K Bouledrak, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Revue De Pneumologie Clinique|October 12, 2010
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)]J Margery, F Rivière, D Planchard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 8, 2015
High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancerE Pailler, N Auger, C R Lindsay, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2017
Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteriaM Tazdait, L Mezquita, J Lahmar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Lung Cancer (Amsterdam, Netherlands)|January 21, 2014
Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?M Macerelli, C Caramella, L Faivre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
Lung Cancer (Amsterdam, Netherlands)|May 3, 2016
Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumorsT Walter, D Planchard, K Bouledrak, et al.
Pageof 6